NO20085243L - Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting - Google Patents

Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting

Info

Publication number
NO20085243L
NO20085243L NO20085243A NO20085243A NO20085243L NO 20085243 L NO20085243 L NO 20085243L NO 20085243 A NO20085243 A NO 20085243A NO 20085243 A NO20085243 A NO 20085243A NO 20085243 L NO20085243 L NO 20085243L
Authority
NO
Norway
Prior art keywords
treatment
pharmaceutical composition
protein
inhibition
viral infections
Prior art date
Application number
NO20085243A
Other languages
English (en)
Inventor
Ulrich Schubert
Original Assignee
Virologik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologik Gmbh filed Critical Virologik Gmbh
Publication of NO20085243L publication Critical patent/NO20085243L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen angår en farmasøytisk sammensetning som omfatter som virksomme komponenter minst én proteasominhibitor og én inhibitor av proteinfoldingsenzymer. Midlene er egnet til behandling av akutte og kroniske infeksjoner med patogene virus for mennesker og dyr.
NO20085243A 2006-06-01 2008-12-15 Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting NO20085243L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006026464A DE102006026464A1 (de) 2006-06-01 2006-06-01 Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
PCT/EP2007/055425 WO2007138116A2 (de) 2006-06-01 2007-06-01 Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus

Publications (1)

Publication Number Publication Date
NO20085243L true NO20085243L (no) 2009-02-27

Family

ID=38626699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085243A NO20085243L (no) 2006-06-01 2008-12-15 Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting

Country Status (15)

Country Link
US (1) US20090156473A1 (no)
EP (1) EP2029125A2 (no)
JP (1) JP2009538881A (no)
KR (1) KR20090048403A (no)
CN (1) CN101453998A (no)
AU (1) AU2007267082A1 (no)
BR (1) BRPI0712459A2 (no)
CA (1) CA2654276A1 (no)
DE (1) DE102006026464A1 (no)
IL (1) IL195611A0 (no)
MX (1) MX2008015259A (no)
NO (1) NO20085243L (no)
RU (1) RU2008152796A (no)
WO (1) WO2007138116A2 (no)
ZA (1) ZA200810531B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
PT1745064E (pt) 2004-04-15 2011-03-23 Proteolix Inc Compostos para a inibição de uma enzima de proteassoma
JP5108509B2 (ja) * 2004-05-10 2012-12-26 プロテオリックス， インコーポレイテッド 酵素阻害のための化合物
ES2396762T3 (es) 2004-12-03 2013-02-26 Dana-Farber Cancer Institute, Inc. Composiciones y métodos para tratar enfermedades neoplásicas
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
US7691852B2 (en) * 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
DE102007031397A1 (de) 2007-07-05 2009-01-08 D2O Bioscience Group Ltd. Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut
DK2207791T4 (da) * 2007-10-04 2019-10-07 Onyx Therapeutics Inc Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
CN102089312A (zh) 2008-05-12 2011-06-08 尼瑞斯药品公司 作为蛋白酶体抑制剂的Salinosporamide衍生物
ES2617560T3 (es) 2008-10-21 2017-06-19 Onyx Therapeutics, Inc. Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
DE102009003992A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Respirationstraktes
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
JP2013500265A (ja) * 2009-07-23 2013-01-07 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス剤として用いられるｍＴＯＲキナーゼ阻害剤
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
CN102051407B (zh) * 2009-11-09 2012-12-12 中国医学科学院医药生物技术研究所 Hiv-1前体蛋白早成熟化诱导剂的筛选方法
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
US9102942B2 (en) 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
CN105477007B (zh) * 2014-09-15 2020-02-18 中国医学科学院药物研究所 大环内酯类药物在抗丝状病毒感染中的应用
CN105675572B (zh) * 2016-03-15 2018-09-14 四川大学华西医院 一种肺癌筛查试剂盒
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11266675B2 (en) * 2018-04-30 2022-03-08 City University Of Hong Kong Methods of treatment of viral infection and uses of anti-HSC70 inhibitors
CN108635584B (zh) * 2018-05-22 2021-12-21 广州威溶特医药科技有限公司 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用
CN110133286A (zh) * 2019-05-20 2019-08-16 吉林大学 Hsp60基因作为靶点在脑膜炎治疗中的医用用途
CN111514299A (zh) * 2020-04-29 2020-08-11 广州中医药大学科技产业园有限公司 一种用于防治肺炎的组合物及其在制备用于防治肺炎的药物中的应用
WO2021231397A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiosaccharides for use in treating coronavirus infection
WO2021263139A1 (en) * 2020-06-26 2021-12-30 Duke University Methods of treating coronavirus infection using hsp90 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
PT1326632E (pt) * 2000-10-12 2007-01-31 Viromics Gmbh Tratamento para o tratamento de infecções por vírus da hepatite
WO2002080907A1 (en) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combination of lactacystin analog and immunosuppressive drug for the prolongation of allograft survival
DE10361944A1 (de) * 2003-12-31 2005-07-28 Viromics Gmbh Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
WO2005115431A2 (en) * 2004-05-24 2005-12-08 Adonia Papathanassiu Methods for inhibiting proteasome and heat shock protein 90
US20060252740A1 (en) * 2005-04-29 2006-11-09 Johnson Robert G Jr Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
WO2007059116A2 (en) * 2005-11-14 2007-05-24 Abraxis Bioscience, Inc. Geldanamycin derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
ZA200810531B (en) 2009-11-25
IL195611A0 (en) 2009-09-01
MX2008015259A (es) 2009-03-26
BRPI0712459A2 (pt) 2012-07-31
DE102006026464A1 (de) 2007-12-06
KR20090048403A (ko) 2009-05-13
US20090156473A1 (en) 2009-06-18
RU2008152796A (ru) 2010-07-20
JP2009538881A (ja) 2009-11-12
WO2007138116A3 (de) 2008-05-08
CN101453998A (zh) 2009-06-10
AU2007267082A1 (en) 2007-12-06
WO2007138116A2 (de) 2007-12-06
EP2029125A2 (de) 2009-03-04
CA2654276A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
CY1112383T1 (el) Αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap)
EA200901308A1 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0606524A2 (pt) derivados de indol para o tratamento de infecções virais
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
ZA200805304B (en) Anti-viral compounds
EA200900298A1 (ru) Ингибиторы вируса гепатита с
WO2008133753A3 (en) Anti-viral compounds
EA200870164A1 (ru) Лечение вирусного гепатита
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA200901241A1 (ru) Соединения для лечения гепатита с
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
EA201000277A1 (ru) Соединения для лечения гепатита с
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EA201171273A1 (ru) Средство для профилактики и лечения высокопатогенных инфекционных заболеваний
NO20053348D0 (no) Farmasoytisk sammensetning for behandling av virusangrep.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application